Burning Rock Biotech (BNR) Operating Leases (2021 - 2026)

Burning Rock Biotech (BNR) has reported Operating Leases for 6 consecutive years, with $4.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Operating Leases rose 47.88% year-over-year to $4.0 million; the TTM figure through Mar 2026 stood at $4.0 million (up 47.88% YoY), while the FY2025 annual figure was $3.5 million, down 51.21% from the prior year.
• Operating Leases came in at $4.0 million for Q1 2026 at Burning Rock Biotech, up from $3.4 million in the prior quarter.
• The five-year high for Operating Leases was $11.1 million in Q2 2024, with the low at $512494.5 in Q4 2023.
• Average Operating Leases over 5 years is $3.6 million, with a median of $2.7 million recorded in 2025.
• Across the five-year window, Operating Leases plunged 82.32% in 2023 and jumped 1387.14% in 2024, its largest moves.
• Year by year, Operating Leases stood at $1.9 million in 2022, then sank by 73.1% to $512494.5 in 2023, then soared by 653.92% to $3.9 million in 2024, then fell by 10.75% to $3.4 million in 2025, then grew by 17.07% to $4.0 million in 2026.
• According to Business Quant data, Operating Leases over the past three periods registered $4.0 million, $3.4 million, and $2.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.